ARTICLE | Product Development
BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows
June 27, 2020 2:09 AM UTC
A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class of therapeutic.
According to BioCentury’s COVID-19 Resource Center, there are more than 100 immunomodulators and immunosuppressants in the clinic to treat COVID-19. New entries this week include therapies from Evelo Biosciences Inc. (NASDAQ:EVLO), Theravance Biopharma Inc. (NASDAQ:TBPH) and Fulcrum Therapeutics Inc. (NASDAQ:FULC)...